Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Raetz

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Best Practice & Research. Clinical Haematology|November 30, 2019
Can Ph-like ALL be effectively targeted?Luke Maese, Elizabeth A Raetz
Hematology. American Society of Hematology. Education Program|December 13, 2012
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?Elizabeth A Raetz, Teena Bhatla
Cancer Investigation|June 18, 2004
Impact of microarray technology in clinical oncologyElizabeth A Raetz, Philip J Moos
Pediatric Blood & Cancer|January 20, 2006
Eliminating a gold standard in childhood acute lymphoblastic leukemia?Elizabeth A Raetz, William L Carroll
Pediatric Blood & Cancer|May 29, 2008
"When can I go home?"-seeking ways to lower the burden on patients and familiesWilliam L Carroll, Elizabeth A Raetz
Current Opinion in Oncology|June 14, 2012
Acute lymphoblastic leukemia in young adults: which treatment?Jennifer L McNeer, Elizabeth A Raetz
Blood|June 27, 2020
How I treat relapsed acute lymphoblastic leukemia in the pediatric populationStephen P Hunger, Elizabeth A Raetz
Blood|March 15, 2014
Refining prognosis in BCR-ABL1-positive ALLElizabeth A Raetz, William L Carroll
Pediatric Blood & Cancer|May 21, 2010
Dying to predict outcomeLaura E Hogan, Elizabeth A Raetz
Journal of Pediatric Hematology/Oncology|August 21, 2010
Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemiaElizabeth A Raetz, Wanda L Salzer
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Best Practice & Research. Clinical Haematology|November 30, 2019
Can Ph-like ALL be effectively targeted?Luke Maese, Elizabeth A Raetz
Hematology. American Society of Hematology. Education Program|December 13, 2012
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?Elizabeth A Raetz, Teena Bhatla
Cancer Investigation|June 18, 2004
Impact of microarray technology in clinical oncologyElizabeth A Raetz, Philip J Moos
Pediatric Blood & Cancer|January 20, 2006
Eliminating a gold standard in childhood acute lymphoblastic leukemia?Elizabeth A Raetz, William L Carroll
Pediatric Blood & Cancer|May 29, 2008
"When can I go home?"-seeking ways to lower the burden on patients and familiesWilliam L Carroll, Elizabeth A Raetz
Current Opinion in Oncology|June 14, 2012
Acute lymphoblastic leukemia in young adults: which treatment?Jennifer L McNeer, Elizabeth A Raetz
Blood|June 27, 2020
How I treat relapsed acute lymphoblastic leukemia in the pediatric populationStephen P Hunger, Elizabeth A Raetz
Blood|March 15, 2014
Refining prognosis in BCR-ABL1-positive ALLElizabeth A Raetz, William L Carroll
Pediatric Blood & Cancer|May 21, 2010
Dying to predict outcomeLaura E Hogan, Elizabeth A Raetz
Journal of Pediatric Hematology/Oncology|August 21, 2010
Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemiaElizabeth A Raetz, Wanda L Salzer
Pageof 16